References
- Australian Institute of Health and Welfare. Cancer in Australia: an overview; 2014.
- Corso A, Arcaini L, Caberlon S, et al. A combination of dexamethasone, cyclophosphamide, etoposide, and cisplatin is less toxic and more effective than high-dose cyclophosphamide for peripheral stem cell mobilization in multiple myeloma. Haematologica. 2002;87:1041–1045.
- Lazzarino M, Corso A, Barbarano L, et al. DCEP (dexamethasone, cyclophosphamide, etoposide, and cisplatin) is an effective regimen for peripheral blood stem cell collection in multiple myeloma. Bone Marrow Transplant. 2001;28:835–839.
- Munshi ND, Jagannath S. Dexamethasone, cyclophosphamide, etoposide and cisplatinum (DCEP): an effective regimen for relapse after high-dose chemotherapy and autologous transplantation. Blood. 1996;88(1):586a.
- Quach H, Prince M, MSAG [Internet]. Clinical practice guideline: multiple myeloma 2012 [updated December 2012; cited 2015 Jul 4]. Available from: http://myeloma.org.au/resources/MSAG_guidlines_v%202%20update%20-due%20Dec%2014.pdf
- Griffin PT, Ho VQ, Fulp W, et al. A comparison of salvage infusional chemotherapy regimens for recurrent/refractory multiple myeloma. Cancer. 2015;121:3622–3630.
- Park S, Lee SJ, Jung CW, et al. DCEP for relapsed or refractory multiple myeloma after therapy with novel agents. Ann Hematol. 2014;93:99–105.
- Valla K, Kaufman JL, Gleason C, et al. editors. Bortezomib in combination with dexamethasone, cyclophosphamide, etoposide, and cisplatin (V-DCEP) for the treatment of multiple myeloma. 56th ASH Annual Meeting and Exposition; 2014; San Francisco, CA.
- Rajkumar SV, Harousseau JL, Durie B, et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011;117:4691–4695.
- Dadacaridou M, Papanicolaou X, Maltesas D, et al. Dexamethasone, cyclophosphamide, etoposide and cisplatin (DCEP) for relapsed or refractory multiple myeloma patients. J BUON. 2007;12:41–44.
- Gerrie AS, Mikhael JR, Cheng L, et al. D(T)PACE as salvage therapy for aggressive or refractory multiple myeloma. Br J Haematol. 2013;161:802–810.